TAGRISSO^™▼ (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
the treatment of adult patients with locally advanced or metastatic EGFR T790M mutations-positive (NSCLC).¹

Prescribing information TAGRISSO
Prescribing information IRESSA® (gefitinib)

Jump to Section...

Prescribing information
Mechanism of action(MOA)
First-line TAGRISSO
Second-line TAGRISSO
References
Contact Us

Report an Adverse Event

First-line TAGRISSO

Baseline characteristics

TAGRISSO was studied across a broad population of patients with NSCLC in FLAURA.²

Thank you for visiting the AstraZeneca Medicines website

This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.

Do you wish to continue?

Cancel Continue

Thank you for visiting the AstraZeneca Medicines website

Do you wish to continue?

Cancel Continue

Validating...

Welcome to AstraZeneca Medicines UK

The content on this website is intended for UK Healthcare Professionals only. The website contains both promotional and non-promotional content.

I am not a UK Healthcare Professional

Welcome to the AstraZeneca Medicines Site

Sorry, your web browser is not supported

Unfortunately, you are using an unsupported browser. Please use Google Chrome 52.0 or Internet Explorer 11 or later. Apologies for any inconvenience.

GB-6911 - June 2017

Cancel

AstraZeneca Medicines

This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Additional Info

Legal Notice and Terms of Use
Privacy Notice
Cookie Policy
Site Map

Contact AstraZeneca

Contact Us
Report Adverse Event

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com or by calling 0800 783 0033.